AU2023325144A1 - Crystalline forms of a pcsk9 inhibitor, compositions and uses - Google Patents

Crystalline forms of a pcsk9 inhibitor, compositions and uses Download PDF

Info

Publication number
AU2023325144A1
AU2023325144A1 AU2023325144A AU2023325144A AU2023325144A1 AU 2023325144 A1 AU2023325144 A1 AU 2023325144A1 AU 2023325144 A AU2023325144 A AU 2023325144A AU 2023325144 A AU2023325144 A AU 2023325144A AU 2023325144 A1 AU2023325144 A1 AU 2023325144A1
Authority
AU
Australia
Prior art keywords
caprate
crystalline form
compound
formula
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023325144A
Other languages
English (en)
Inventor
Lorenzo CODAN
Richard Desmond
Artis Klapars
Jongrock Kong
Patrick LARPENT
Alfred Lee
Peter E. Maligres
Tiffany PIOU
Lee ROBISON
Carlos Alberto Pons SIEPERMANN
Fuh-Rong Tsay
Richard J. Varsolona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Werthenstein BioPharma GmbH
Merck Sharp and Dohme LLC
Original Assignee
Werthenstein BioPharma GmbH
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werthenstein BioPharma GmbH, Merck Sharp and Dohme LLC filed Critical Werthenstein BioPharma GmbH
Publication of AU2023325144A1 publication Critical patent/AU2023325144A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2023325144A 2022-08-17 2023-08-16 Crystalline forms of a pcsk9 inhibitor, compositions and uses Pending AU2023325144A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263371690P 2022-08-17 2022-08-17
US63/371,690 2022-08-17
US202263384298P 2022-11-18 2022-11-18
US63/384,298 2022-11-18
PCT/US2023/072326 WO2024040125A1 (en) 2022-08-17 2023-08-16 Crystalline forms of a pcsk9 inhibitor, compositions and uses

Publications (1)

Publication Number Publication Date
AU2023325144A1 true AU2023325144A1 (en) 2025-01-30

Family

ID=89942405

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023325144A Pending AU2023325144A1 (en) 2022-08-17 2023-08-16 Crystalline forms of a pcsk9 inhibitor, compositions and uses

Country Status (10)

Country Link
US (1) US20260035411A1 (https=)
EP (1) EP4573104A1 (https=)
JP (1) JP2025527471A (https=)
KR (1) KR20250048468A (https=)
CN (1) CN119731194A (https=)
AU (1) AU2023325144A1 (https=)
CO (1) CO2025001998A2 (https=)
IL (1) IL319006A (https=)
MX (1) MX2025001887A (https=)
WO (1) WO2024040125A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026032253A1 (zh) * 2024-08-06 2026-02-12 石药集团中奇制药技术（石家庄）有限公司 环肽类似物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019246405A1 (en) * 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Cyclic polypeptides for pcsk9 inhibition
US11306125B2 (en) * 2018-06-21 2022-04-19 Merck Sharp & Dohme Corp. PCSK9 antagonists bicyclo-compounds
IL279363B2 (en) * 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
EP4021919A1 (en) * 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds

Also Published As

Publication number Publication date
CN119731194A (zh) 2025-03-28
IL319006A (en) 2025-04-01
EP4573104A1 (en) 2025-06-25
JP2025527471A (ja) 2025-08-22
US20260035411A1 (en) 2026-02-05
KR20250048468A (ko) 2025-04-08
CO2025001998A2 (es) 2025-03-17
WO2024040125A1 (en) 2024-02-22
MX2025001887A (es) 2025-03-07

Similar Documents

Publication Publication Date Title
CN111432803B (zh) 包含血浆激肽释放酶抑制剂的剂型
JP6838744B2 (ja) Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
KR101645069B1 (ko) 피르페니돈 및 약학적으로 허용가능한 부형제의 캡슐 제제
KR101544766B1 (ko) Ｃｄｄｏ 메틸 에스테르의 신규한 형태
US10898471B2 (en) Methods of inhibiting leukotriene A4 hydrolase
US20240261282A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
KR102759845B1 (ko) 2-｛4-[n-(5,6-디페닐피라진-2-일)-n-이소프로필아미노]부틸옥시｝-n-(메틸술포닐)아세트아미드를 함유하는 의약 조성물
EP2858989B1 (en) Amorphous form of an akt inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof
US20260035411A1 (en) Crystalline forms of a pcsk9 inhibitor, compositions and uses
CN103553996B (zh) 抗胆碱药物组合物
US20240238367A1 (en) Compounds for treating conditions related to pcsk9 activity
CN100584835C (zh) 桂哌齐特的药用盐及其制备方法
JP2021504312A (ja) 血漿カリクレイン阻害剤を含む剤形
CN115887395A (zh) 恩杂鲁胺固体分散体制剂及其制备方法和应用
JP2020505363A (ja) オキサジン誘導体を含む医薬組成物、およびこの医薬組成物のアルツハイマー病の処置または予防での使用
MX2010014524A (es) Formulaciones de dosificacion solida de telcagepant potásico.
KR20230027388A (ko) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제
CN104434857A (zh) 一种含有洛伐他汀的口服固体制剂及其制备工艺
CN113456596A (zh) 一种双醋瑞因颗粒及其制备方法和包含双醋瑞因颗粒的固体制剂
CN104490800A (zh) 一种福司氟康唑冻干粉组合物及其制备方法
EP3184095A1 (en) Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
EA045975B1 (ru) Кристаллическая l-аргининовая соль (r)-2-(7-(4-циклопентил-3-(трифторметил)бензилокси)-1,2,3,4-тетрагидроциклопента[b]индол-3-ил)уксусной кислоты (соединения 1) для применения при расстройствах, связанных с s1p1-рецептором
CN104983690A (zh) 一种治疗冠心病的药物阿托伐他汀钙组合物干混悬剂
HK1198010B (en) A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis
HK1198010A (en) A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis